Detail of "21406-61-1"

Reference

Allylic selenides in organic synthesis: new methods for the synthesis of allylic amines

Allylic selenides in organic synthesis: new methods for the synthesis of allylic amines. Shea, Regan G.; Fitzner, Jeffrey N.; Fankhauser, John E.; Spaltenstein, Andreas; Carpino, Philip A.; Peevey, Richard M.; Pratt, Daniel V.; Tenge, Bradley J.; Hopkins, Paul B. (Dep. Chem., Univ. Washington, Seattle, WA 98195, USA). J. Org. 91230-13-6 which is the cas registry number is also used here. Chem., 51(26), 5243-52 (English) 1986. CODEN: JOCEAH. ISSN: 0022-3263. DOCUMENT TYPE: Journal CA Section: 21 (General Organic Chemistry) Section cross-reference(s): 34 Oxidative rearrangement of allylic selenides in the presence of various amine nucleophiles provides synthetic access to a variety of allylic amine derivs. The stereochem. outcome of these reactions has been investigated, and is consistent with a [2,3]-sigmatropic rearrangement mechanism. Several D-a-amino acids and racemic b,g-unsatd. a-amino acids were prepd. in this manner. A variant of this process employing an achiral allylic selenide and chiral amide afforded protected allylic amines in low diastereoisomeric excess. .

Preparation of novel bicyclic and tricyclic cannabinoids with binding selectivity for the CB2 cannabinoid receptor

Preparation of novel bicyclic and tricyclic cannabinoids with binding selectivity for the CB2 cannabinoid receptor. Makriyannis, Alexandros; Nikas, Spyridon P.Several substances are used for example 487578-69-8 which is its cas registry number.; Khanolkar, Atmaram D. ( University of Connecticut, USA). PCT Int. Appl. WO 2003005960 A2 23 Jan 2003, 53 pp. DESIGNATED STATES: W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K. APPLICATION: WO 2002-US21961 11 Jul 2002. PRIORITY: US 2001-PV305228 13 Jul 2001. DOCUMENT TYPE: Patent CA Section: 30 (Terpenes and Terpenoids) Section cross-reference(s): 1, 63 Novel bicyclic-cannabinoids and hexahydrocannabinol analogs, such as I and II [R1, R2 = H, OH, NH2, NO2, CN, halogen, alkyl, alkoxy, acyl, etc.; R4 = alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, etc.; R5 = R6 = Me; R5R6 = (CH2)4, SCH2CH2S, connecting group forming a cycloalkyl or heterocyclyl; X = CH2, CO, CH(OH), CH(N3), etc.], were prepd. for pharmaceutical use and have selective binding affinity for the CB2 receptor. These compds., when administered in a therapeutically effective amt. 487578-92-7 and 21406-61-1 are cas registry numbers of chemicals which are used as reagents here. to an individual or animal, result in a sufficiently high level of that compd. in the individual or animal to cause a physiol. response useful to treat a no. of physiol. conditions, such as pain, peripheral pain, glaucoma, epilepsy, nausea, such as assocd. with cancer chemotherapy, AIDS Wasting Syndrome, cancer, neurodegenerative diseases, including Multiple Sclerosis, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, and can also be used to enhance appetite, to reduce fertility, to prevent or reduce diseases assocd. with motor function such as Tourette's syndrome, to provide neuroprotection, to produce peripheral vasodilation and to suppress memory. Thus, bicyclic terpene cannabinoid analog III was via a multistep synthetic sequence starting from phenyltriphenylphosphonium bromide, 1-(3,5-dimethoxyphenyl)cyclopentanecarboxaldehyde, and a mixt. of nopinone diacetates. III was then cyclized using TMSOTf in CH2Cl2 and MeNO2 to give the corresponding cannabinol II [R4 = (CH2)5Me, R5R6 = (CH2)4, X = CO] in 75% yield. The prepd. cannabinoids were tested for cannabinoid receptor binding activity with some analogs showing comparative IC50 values in the range of 0.1 nM and 10.0 nM for the CB1 and CB2 receptors, resp. ..